Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 8/20 | 0.44 |
| ▸ | NQO2 | P16083 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.37 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.37 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.37 |
| ▸ | FAAH | O00519 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6027134 | 0.91 | NQO2 (0.45) | HSD11B1NQO2L3MBTL1EPHX2KMT2A | |
| SCHEMBL6026353 | 0.81 | EPHX2 (0.51) | HSD11B1EPHX2KMT2A | |
| SCHEMBL6879816 | 0.80 | NPC1 (0.47) | NQO2KMT2A | |
| SCHEMBL6026919 | 0.72 | EPHX2 (0.47) | HSD11B1EPHX2KMT2A | |
| SCHEMBL6026939 | 0.72 | NPY5R (0.64) | NQO2 | |
| SCHEMBL14381771 | 0.71 | L3MBTL1 (0.48) | HSD11B1L3MBTL1KMT2APOLB | |
| SCHEMBL6026920 | 0.69 | EPHX2 (0.47) | EPHX2KMT2A | |
| SCHEMBL6026524 | 0.69 | EPHX2 (0.47) | EPHX2KMT2A | |
| SCHEMBL14082229 | 0.69 | KMT2A (0.53) | HSD11B1L3MBTL1KMT2AFAAH | |
| SCHEMBL14082546 | 0.69 | MKNK1 (0.57) | HSD11B1L3MBTL1KMT2AFAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1613310-A1 | IMIDAZOLE DERIVATIVES FOR TREATMENT OF ALLERGIC AND HYPERPROLIFERATIVE DISORDERS | Avanir Pharmaceuticals (US) | 2006-01-11 | — | — | EP | disclosed |
| US-20040229927-A1 | Imidazole derivatives for treatment of allergic and hyperproliferative disorders | AVANIR PHARMACEUTICALS | 2004-11-18 | — | — | US | disclosed |
| WO-2004091610-A1 | IMIDAZOLE DERIVATIVES FOR TREATMENT OF ALLERGIC AND HYPERPROLIFERATIVE DISORDERS | AVANIR PHARMACEUTICALS (US) | 2004-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229927-A1 | Imidazole derivatives for treatment of allergic and hyperproliferative disorders | ICOS, TSLP, IKZF3 | HSD11B1 3584/4885NQO2 1625/4885L3MBTL1 1510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.